IRS1 and breast carcinoma: The presence of IRS2 inhibited the ability of IRS1 to sensitize myeloblast-like and breast cancer cells to taxol, etoposide, and vincristine therapy [51, 52] and silencing of IRS2 potentiates the effects of ruxolitinib in myeloproliferative neoplasms cells [53].